Harnessing IgM for solid tumor therapy: biology, engineering advances, and translational challenges

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Immunoglobulin M (IgM) antibodies are emerging as a promising next-generation platform for cancer immunotherapy.
• IgM offers distinct biological advantages over IgG, including higher avidity, potent complement activation, and better recognition of diverse tumor antigens in immunosuppressive environments.

Purpose of the Study:

• To review the structure, biology, and therapeutic potential of IgM antibodies for solid tumor treatment.
• To highlight advancements in engineering novel IgM formats and discuss translational challenges and opportunities.

Main Methods:

• Review of current scientific literature on IgM antibodies in cancer immunotherapy.
• Analysis of preclinical and early translational studies on engineered IgM formats.
• Examination of structural, biophysical, and manufacturing considerations for IgM development.

Main Results:

• Engineered IgM formats demonstrate significant antitumor potential in preclinical models.
• IgM's multivalent binding, complement activation, and antigen recognition offer advantages for solid tumors.
• Key challenges include short serum half-life, tumor penetration, complexity, and production scalability.

Conclusions:

• IgM antibodies hold significant therapeutic promise for solid tumor treatment.
• Further research and development are needed to overcome translational barriers for clinical application.
• IgM represents a potential cornerstone for future antibody-based cancer immunotherapies.